Published in
American Society of Hematology, Blood, 11(132), p. 1095-1105
DOI: 10.1182/blood-2018-05-850339
Links
Tools
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Journal article published in 2018 by
Josephine D. Kahn,
Peter G. Miller 
,
Alexander J. Silver ,
Rob S. Sellar,
Shruti Bhatt,
Christopher Gibson,
Marie McConkey,
Dylan Adams,
Brenton Mar,
Philipp Mertins,
Shaunt Fereshetian,
Karsten Krug,
Haoling Zhu,
Anthony Letai,
Steven A. Carr
and other authors.
,
Alexander J. Silver ,
Rob S. Sellar,
Shruti Bhatt,
Christopher Gibson,
Marie McConkey,
Dylan Adams,
Brenton Mar,
Philipp Mertins,
Shaunt Fereshetian,
Karsten Krug,
Haoling Zhu,
Anthony Letai,
Steven A. Carr
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Truncating PPM1D mutations confer chemotherapy resistance, leading to the selective expansion of PPM1D-mutant cells in vitro and in vivo. PPM1D inhibitor treatment reverses the chemotherapy-resistance phenotype and selectively kills PPM1D-mutant cells.